Back to Journals » Clinical Ophthalmology » Volume 14

Diabetic Population-Based Model to Estimate Impact of Ranibizumab on Diabetic Retinopathy Severity in Patients with Diabetic Macular Edema

Authors Varma R, Bressler NM, Doan QV, Suñer IJ, Danese M, Dolan CM, Lee A, Ehrlich JS, Rajput Y

Received 1 November 2019

Accepted for publication 4 March 2020

Published 7 May 2020 Volume 2020:14 Pages 1249—1259

DOI https://doi.org/10.2147/OPTH.S236636

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Scott Fraser


Rohit Varma,1 Neil M Bressler,2 Quan V Doan,3 Ivan J Suñer,4 Mark Danese,3 Chantal M Dolan,5 Abraham Lee,3 Jason S Ehrlich,5 Yamina Rajput5

1Southern California Eye Institute, CHA Hollywood Presbyterian Medical Center, Los Angeles, CA, USA; 2Johns Hopkins University, Baltimore, MD, USA; 3Outcomes Insights, Inc., Westlake Village, CA, USA; 4Retina Associates of Florida, Tampa, FL, USA; 5Genentech, Inc., South San Francisco, CA, USA

Correspondence: Rohit Varma
Southern California Eye Institute, CHA Hollywood Presbyterian Medical Center, 1300 N. Vermont Avenue, Los Angeles, CA 90027, USA
Tel +1 833 270 3937
Email rvarma@sceyes.org

Purpose: Estimate effects of ranibizumab on diabetic retinopathy (DR) severity in US Hispanic and non-Hispanic white persons with center-involved diabetic macular edema (DME) causing vision impairment for whom ranibizumab treatment would be considered.
Patients and Methods: This model simulated DR severity outcomes over 2 years in the better-seeing eye using US census, National Health and Nutrition Examination Survey, Wisconsin Epidemiologic Study of Diabetic Retinopathy, and Los Angeles Latino Eye Study data. Baseline DR severity estimated from Diabetic Retinopathy Clinical Research Network trial data. Changes in DR severity after 2 years, with/without monthly ranibizumab (0.3 or 0.5 mg), were estimated from Phase III clinical trial data (RIDE/RISE) using a 2-dimensional Monte Carlo simulation model. Number of patients over a 2-year period for whom 1) DR severity worsening was avoided, 2) DR severity improved, and 3) selected clinical events related to proliferative DR (PDR) occurred, was estimated.
Results: An estimated 37,274 US Hispanic and non-Hispanic white persons were projected to have DR with center-involved DME and be eligible for ranibizumab treatment. The number of persons with moderately severe non-proliferative DR (NPDR) or less severe DR at baseline who would worsen to PDR and experience a PDR complication over 2 years would be reduced from 437 with no ranibizumab to 19 with ranibizumab (95% reduction; 95% simulation interval [SI], 79– 100%). The number of persons with severe NPDR or less severe DR at baseline who would be expected to improve by ≥ 2 DR severity levels over 2 years would increase from 1706 with no ranibizumab to 13,042 with ranibizumab (682% increase; 95% SI, 478– 967%).
Conclusion: This model estimates that ranibizumab treatment in US Hispanic and non-Hispanic white patients with center-involved DME causing vision impairment would potentially reduce the number of patients with worsening DR and potentially increase the number with DR improvements.

Keywords: diabetic macular edema, diabetic retinopathy, population-based model

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]